These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1028796)

  • 1. Quality assurance for medical products: unified program for all federal agencies.
    Flaherty FJ
    Hosp Formul; 1976 Dec; 11(12):669, 674, 679. PubMed ID: 1028796
    [No Abstract]   [Full Text] [Related]  

  • 2. Assuring total drug quality.
    Simmons HE
    J Am Pharm Assoc; 1973 Feb; 13(2):96-8. PubMed ID: 4686621
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug product quality.
    Exp Med Surg; 1971; 29(1):135-44. PubMed ID: 5147595
    [No Abstract]   [Full Text] [Related]  

  • 4. Assuring the quality of the nation's drugs. Interview by William E. Small.
    Michels D
    Am Pharm; 1980 Apr; NS20(4):40-2. PubMed ID: 7386377
    [No Abstract]   [Full Text] [Related]  

  • 5. Securing the US pharmaceutical supply.
    Somberg JC
    Am J Ther; 2008; 15(3):197. PubMed ID: 18496255
    [No Abstract]   [Full Text] [Related]  

  • 6. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The regulation of biopharmaceuticals.
    Weisbroth N
    Qual Assur; 1993; 2(1-2):147-51. PubMed ID: 8156202
    [No Abstract]   [Full Text] [Related]  

  • 8. Controlling the quality of Uncle Sam's drugs.
    Hecht A
    FDA Consum; 1977 May; 11(4):22-3. PubMed ID: 10316531
    [No Abstract]   [Full Text] [Related]  

  • 9. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract]   [Full Text] [Related]  

  • 11. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory aspects of parenteral drugs.
    Jennings J
    Bull Parenter Drug Assoc; 1972; 26(2):53-7. PubMed ID: 5012204
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug Product Problem Reporting Program.
    FDA Drug Bull; 1979 Aug; 9(3):18. PubMed ID: 467875
    [No Abstract]   [Full Text] [Related]  

  • 14. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 15. World agencies try to stem flood of fake drugs.
    Surendran A
    Nat Med; 2004 Feb; 10(2):111. PubMed ID: 14760401
    [No Abstract]   [Full Text] [Related]  

  • 16. The relationship between the pharmaceutical industry and government agencies.
    Johnston RV
    J Am Vet Med Assoc; 1965 Dec; 147(12):1588-92. PubMed ID: 5884057
    [No Abstract]   [Full Text] [Related]  

  • 17. The intensified drug inspection program: procedures and results.
    Clevenger WL
    Bull Parenter Drug Assoc; 1969; 23(6):263-8. PubMed ID: 5355888
    [No Abstract]   [Full Text] [Related]  

  • 18. QUAD routes out inferior drugs.
    Can Hosp; 1973 May; 50(5):58-9. PubMed ID: 4779804
    [No Abstract]   [Full Text] [Related]  

  • 19. Products in the U.S. pipeline. Pharmaceutical Manufacturers Association.
    Biotechnology (N Y); 1991 Oct; 9(10):947-9. PubMed ID: 1367805
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. United States Food and Drug Administration's viewpoint.
    Ley HL; Desmond FH
    Can Med Assoc J; 1968 Feb; 98(6):318-21. PubMed ID: 5636100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.